Detalhe da pesquisa
1.
Response to: "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis".
J Anaesthesiol Clin Pharmacol
; 34(4): 548, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30774242
2.
Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.
Pain
; 163(6): 1006-1018, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34510135
3.
Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.
Pain
; 161(11): 2446-2461, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32520773
4.
When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
Arthritis Rheumatol
; 68(2): 382-91, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26554876